--- title: 'Research Daily Summary: What Happened on November 9, 2026' headline: Gene editing kept ANGPTL3 suppressed in primates for up to three years description: Other studies tested a cell-division mechanism, gait-based health predictions and a heart-repair treatment in mice. url: https://thebench.bio/news/research/2026-11-09 topic: research date: '2026-11-09' covers: - '2026-11-09' date_published: '2026-11-09T12:02:59Z' date_modified: '2026-11-10T00:02:29Z' tags: - Industry - Research - Clinical - Manufacturing - Software sources: 10 publisher: TheBench.Bio --- # Research Daily Summary: What Happened on November 9, 2026 **Gene editing kept ANGPTL3 suppressed in primates for up to three years** Other studies tested a cell-division mechanism, gait-based health predictions and a heart-repair treatment in mice. ## Today in brief A single CRISPR base-editing treatment cut ANGPTL3 protein by more than 90% in nonhuman primates, with suppression observed for up to three years. [1] VERVE-201 is now in a first-in-human trial, but researchers still need to establish its long-term safety and whether it reduces cardiovascular events. [1] E2F1 restarted cell division without broadly changing chromatin accessibility, while an experimental mRNA treatment improved heart function in mice after a heart attack. [2] [3] A gait model improved health-trait predictions across body systems, and researchers linked ulcerative-colitis response patterns to vedolizumab outcomes. [4] [5] ## One gene-editing dose suppressed ANGPTL3 in primates for up to three years A single dose of a CRISPR adenine base editor reduced circulating ANGPTL3 protein by more than 90% in nonhuman primates, with suppression observed for up to three years. [1] In mouse and primate models with elevated blood lipids, inactivating ANGPTL3 substantially lowered LDL cholesterol and triglycerides. [1] Tests in human liver cells found no detectable unintended edits among about 3,000 candidate genomic sites examined and no treatment-related structural DNA changes. [1] Those tests cannot establish long-term safety, and animal results may not predict lasting cholesterol reductions in people. [1] VERVE-201, an investigational therapy targeting ANGPTL3, is being tested in a first-in-human trial for severe, treatment-resistant hypercholesterolemia. [1] ## E2F1 can restart cell division without broadly opening packed DNA University of California, Santa Cruz researchers found that E2F1 can activate cell-cycle genes and prompt dormant cells to divide without widespread changes to chromatin accessibility, or how open DNA is to cellular machinery. [2] Removing E2F1’s DNA-binding domain prevented cells from reentering the cell cycle. [2] Without additional growth signals, the cells divided no more than three times. E2F1 acted faster than the usual nutrient-dependent route to cell division. [2] The researchers said they don’t yet understand how E2F1 activates genes without substantial chromatin changes or how cancers might exploit the process. [2] ## A gait model predicted health traits across most body systems A model trained on skeletal-motion recordings from 3,328 adults improved predictions for 1,887 of 3,210 health-phenotype targets. [4] Participants provided movement data while completing five motor tasks. [4] The model improved predictions across all 18 body systems for men and 17 of 18 for women, as well as predictions of diagnoses and medication use. [4] ## Mouse mRNA treatment improved heart function after a heart attack Mice given an experimental mRNA treatment after a heart attack pumped about 10% more blood per heartbeat than mock-treated animals and showed signs of heart-muscle growth and tissue repair. [3] Improved heart function remained evident at follow-ups 28 days and 12 weeks after treatment. The study reported no adverse effects. [3] The researchers plan more animal studies while refining the treatment before starting human trials. [3] ## Ulcerative-colitis response patterns tracked with vedolizumab outcomes Analysis of a 768-participant comparative trial identified four patient-reported response patterns for both vedolizumab and adalimumab. [5] In a separate 576-participant trial, vedolizumab response groups were associated with remission at one year and longer-term complications. [5] Over seven years, patients in faster-response groups had a lower risk of hospitalization or colectomy than those in slower-response groups, with a hazard ratio of 0.56 and a 95% confidence interval of 0.34 to 0.93. [5] Molecular analyses associated vascular inflammation, including interactions between SPP1-positive macrophages and endothelial cells, with vedolizumab nonresponse. [5] In two real-world cohorts, renin–angiotensin system inhibitor use alongside vedolizumab was associated with fewer long-term complications. The study authors said prospective validation is needed before using the approach to select combination treatment. [5] ## Also worth knowing - A University of Pennsylvania-led team used a placenta-on-a-chip model to find that lower cadmium exposures impaired glucose transfer and hormone production, increased barrier permeability and inflammation, and altered metabolism, even when most cells remained intact. [6] - A review proposed that shifts in cancer-cell states may help childhood tumors spread without first acquiring additional mutations, drawing on evidence from neuroblastoma, Ewing sarcoma, osteosarcoma, medulloblastoma and rhabdomyosarcoma. [7] - AbbVie opened an additional 12,000-square-foot Oxford research site for immunology, neuroscience and oncology, as part of more than £120 million in UK research, academic-collaboration and talent-development investment and commitments. [8] - Researchers introduced the DIY Biofabrication Atlas, a public resource organizing open-source biomanufacturing hardware with standardized information on cost, components and performance. [9] - Stanford researchers used heparan sulfate antibodies to investigate how dysregulation of the brain’s endothelial glycocalyx may contribute to blood–brain barrier dysfunction in aging and neurodegenerative disease. [10] ## The day in numbers - **More than 90%**: ANGPTL3 protein suppression observed after one gene-editing dose in nonhuman primates. [1] - **Up to 3 years**: Duration of ANGPTL3 suppression observed in nonhuman primates after one treatment. [1] - **1,887 of 3,210**: Health-phenotype targets predicted by the gait model. [4] - **About 10%**: Increase in blood pumped per heartbeat in treated mice compared with mock-treated animals after a heart attack. [3] ## Also published - [FAQ: What’s Holding Back the Shift From IV to Subcutaneous Antibodies?](), BioPharm International - [Familial hypercholesterolemia linked to increased odds of preeclampsia](), Clinical Trials Arena - [Linking lessons on EGFR](), Practical Fragments - [Researchers sue to block NSF from demolishing social science directorate](), Science News - [Jon Clardy, 1943-2026](), In the Pipeline - [Welcome: Ilya Osterman](), EMBL - [Neurons in a dish are the newest computing machines](), Science News - [Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress](), Nature Reviews Drug Discovery - [Histone lysine demethylases in the third decade: biology and therapeutic prospects](), Nature Reviews Drug Discovery - [Craft and engineering](), Nature Reviews Bioengineering ## Sources 1. [One-Time CRISPR Gene Editing Shows Lasting Cholesterol Reduction](), Inside Precision Medicine, 2026-11-09 2. [How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome](), GEN, 2026-11-09 3. [mRNA Therapy Promotes Cellular Repair After Heart Attack ](), Inside Precision Medicine, 2026-11-09 4. [Deep learning-based gait analysis predicts multisystem health phenotypes](), Nature Medicine, 2026-11-09 5. [An ulcerative colitis taxonomy defined by individual patient-reported response trajectories](), Nature Medicine, 2026-11-09 6. [Investigating toxin exposure with a placenta-on-a-chip model](), BioTechniques, 2026-11-09 7. [Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests](), GEN, 2026-11-09 8. [AbbVie expands Oxford R&D facility with new £120m UK research commitment](), Pharmafile, 2026-11-09 9. [Open-source hardware for biomanufacturing](), Nature Reviews Bioengineering, 2026-11-09 10. [Combatting blood–brain barrier breakdown in age-related neurological diseases](), BioTechniques, 2026-11-09 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: [7]: [8]: [9]: [10]: